Quick Answer
Atea Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $95.71 million for the year ending 2025.
- Atea Pharmaceuticals, Inc. showed an increase of +47.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Atea Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $25.60 million | Q1 2020: $17.15 million | Q2 2020: $115.79 million | Q3 2020: $105.38 million | Q1 2021: $833.75 million | Q2 2021: $816.46 million | Q3 2021: $839.66 million | Q1 2022: $705.55 million | Q2 2022: $684.48 million | Q3 2022: $176.41 million | Q1 2023: $183.26 million | Q2 2023: $213.70 million | Q3 2023: $137.89 million | Q1 2024: $160.91 million | Q2 2024: $243.39 million | Q3 2024: $98.46 million | Q1 2025: $119.39 million | Q2 2025: $87.72 million | Q3 2025: $77.34 million.
- Over the full 8 years of available data (2018 to 2025), Atea Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 177.5%.
- Historical annual values: Fiscal year 2025: $95.71 million | Fiscal year 2024: $64.70 million | Fiscal year 2023: $143.82 million | Fiscal year 2022: $188.46 million | Fiscal year 2021: $764.38 million | Fiscal year 2020: $850.12 million | Fiscal year 2019: $21.66 million | Fiscal year 2018: $34.49 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: